GLP-1 weight-loss drugs like Ozempic slash heart attack and stroke risk, study finds

The GLP-1 receptor agonist class had a clear remit when first approved for type 2 diabetes. Over the past six years, clinical work on weight loss, cardiovascular disease reduction and kidney protection has demonstrated the class sits at the endocrinology-cardiology crossroads. A new Yale University meta-analysis published this month engages that crossroads in the widest frame yet.

The study covers 17 randomised controlled trials and a total of 124,000 patients. The dataset spans semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), liraglutide and dulaglutide. Main result: a 20 per cent reduction in heart attack risk, and a 26 per cent reduction in stroke risk. All-cause mortality dropped by 14 per cent.

The patient profile is diverse: 58 per cent had obesity (BMI ≥ 30), 42 per cent were overweight but not obese; 47 per cent had pre-existing cardiovascular disease, while 53 per cent fell into the primary-prevention category. The drug effect was seen in both groups; risk reduction was 18 per cent in primary prevention and 29 per cent in secondary prevention. The gap implies the drug carries stronger effect in higher-risk patients.

The mechanism question is important. Do GLP-1 agonists deliver cardiovascular protection only through weight loss? The study's sub-analysis showed weight loss accounted for 35-40 per cent of the contribution, with the remaining 60-65 per cent coming from direct cardiovascular effects. The class's positive impact on blood pressure, inflammation (CRP), cholesterol profile and endothelial function is documented. The Yale team's conclusion: "This class carries multimodal effects beyond weight loss."

Dr Harlan Krumholz, lead author from Yale School of Medicine's cardiology division, said in the JAMA analysis commentary: "This could launch one of the largest protocol changes in cardiology practice." Krumholz noted that current American Heart Association (AHA) and European Society of Cardiology (ESC) guidelines recommend the GLP-1 class as second-line therapy for high-risk cardiovascular patients, but predicted that with the new data the scope of primary-prevention recommendations would broaden.

Drug cost remains the central access issue. Ozempic costs USD 935 per month in the US; Wegovy USD 1,349. Neither is covered by Medicare. Mounjaro is USD 1,084 a month. Insurance coverage is higher for type 2 diabetes, but the weight-loss indication is typically out-of-pocket. In Türkiye, the Social Security Institution (SGK) has reimbursed Ozempic for obese patients since 2025, with patient out-of-pocket monthly payments around 250-400 TL. European prices range between EUR 80 and 200.

Strong competition between Novo Nordisk and Eli Lilly has shifted price-production dynamics in the last three years. Novo Nordisk has invested EUR 6.7 billion in Germany and Belgium to double Wegovy production capacity; Eli Lilly invested USD 8.5 billion in two new US plants in the same period. By end-2027, global GLP-1 production capacity is targeted to reach an annual 350 million patient-treatment periods.

Safety profile is documented in detail in the study. Gastrointestinal side effects (nausea, vomiting, diarrhoea, constipation) are most common; 45-65 per cent of patients experience them, though they usually decline at 4-8 weeks. Pancreatitis occurs in 0.3-0.5 per cent; thyroid C-cell tumour risk was seen in animal studies but has not been confirmed in humans. The study notes that the risk of Non-Arteritic Ischemic Optic Neuropathy was measured at 2 per cent — a newer concern that has surfaced in the last six months.

Globally, in November 2025 the WHO added the GLP-1 class to its "essential medicines" list for the type 2 diabetes indication. Adding the weight-loss indication will fall in the 2027 review cycle. WHO Director-General Tedros Adhanom Ghebreyesus said US-anchored high prices were "deepening global inequality"; the Indian-Brazilian generic-producer lobby contested patent extension processes at a Geneva meeting in March 2026.

Finally, the study has an ethical and social dimension. Krumholz said in his JAMA editorial: "The widespread use of this class has the potential to shift the population-level curve of obesity and cardiovascular disease. But this positive effect is only possible if the medicine is delivered with equitable access." The message will be debated at the AHA's annual congress in June.

For cardiovascular or diabetes treatment decisions, please consult a qualified endocrinologist or cardiologist; this article does not substitute for medical advice.